New developments in the treatment of squamous cell lung cancer

Current Opinion in Oncology

Volumn 26, Issue 2, 2014, Pages 152-158

  Filipits, Martin ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Genomic characterization; Lung cancer; Next generation sequencing; Somatic mutations; Targeted therapy

Indexed keywords

CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION;

EID: 84894066394     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000049     Document Type: Review

References (29)

1. Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: Relevance for clinical practice and clinical trials. J Clin Oncol 2013; 31:992-1001
2. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage nonsmall-cell lung cancer. J Clin Oncol 2008; 26:3543-3551
3. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006; 107:1589-1596
4. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for nonsmall-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet 2009; 374:1432-1440
5. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic nonsmall-cell lung cancer. J Clin Oncol 2004; 22:2184-2191
6. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for nonsmall-cell lung cancer. N Engl J Med 2006; 355:2542-2550
7. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous nonsmall-cell lung cancer: AVAil. J Clin Oncol 2009; 27:1227-1234
8. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489:519-525
9. Hirsch FR, Janne PA, Eberhardt WE, et al. Epidermal growth factor receptor inhibition in lung cancer: Status 2012. J Thorac Oncol 2013; 8:373-384
10. Rekhtman N, Ang DC, Sima CS, et al. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-Tissue sections with validation in small specimens. Mod Pathol 2011; 24:1348-1359
11. Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced nonsmall-cell lung cancer: Analysis of data from the phase 3 FLEX study. Lancet Oncol 2012; 13:33-42
12. O'Byrne KJ, Gatzemeier U, Bondarenko I, et al. Molecular biomarkers in nonsmall-cell lung cancer: A retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 2011; 12:795-805
13. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced nonsmall-cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 2009; 373:1525-1531
14. Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010; 2:62-93
15. Dutt A, Ramos AH, Hammerman PS, et al. Inhibitor-sensitive FGFR1 amplification in human nonsmall cell lung cancer. PLoS One 2011; 6:e20351
16. Kohler LH, Mireskandari M, Knosel T, et al. FGFR1 expression and gene copy numbers in human lung cancer. Virchows Arch 2012; 461:49-57
17. Sasaki H, Shitara M, Yokota K, et al. Increased FGFR1 copy number in lung squamous cell carcinomas. Mol Med Rep 2012; 5:725-728
18. Tran TN, Selinger CI, Kohonen-Corish MR, et al. Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in nonsmall cell lung cancer. Lung Cancer 2013; 81:462-467
19. Sierra JR, Tsao MS. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol 2011; 3:S21-S35
20. Dziadziuszko R, Wynes MW, Singh S, et al. Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in nonsmall cell lung cancer. J Thorac Oncol 2012; 7:340-347
21. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-1043
22. Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a nonsmall cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011; 6:942-946
23. Gherardi E, Birchmeier W, Birchmeier C, et al. Targeting MET in cancer: Rationale and progress. Nat Rev Cancer 2012; 12:89-103
24. Spigel DR, Ervin TJ, Ramlau RA, et al. Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2013; 31:4105-4114
25. Amzel LM, Huang CH, Mandelker D, et al. Structural comparisons of class I phosphoinositide 3-kinases. Nat Rev Cancer 2008; 8:665-669
26. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-264
27. Boland JM, Kwon ED, Harrington SM, et al. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer 2013; 14:157-163
28. Topalian SL, Brahmer JR, Hodi FS, et al. Anti-PD-1 (BMS-936558,MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response. J Clin Oncol 2012; 30:; abstract CRA2509
29. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723